A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents Business Overview Recursion is a clinical-stage TechBio company with a mission to decode biology to radically improve lives. We have advanced a portfolio of differentiated internal programs and strategic partnerships powered by our integrated drug discovery and development platform, the Recursion Operating System (OS). This platform provides end-to-end, AI-native capabilities that span from novel biological ideas through the clinic, integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. All of our technologies are designed to translate complex science into medicines that matter — faster, better, and at scale — for patients who are waiting. Historically, it has taken over ten years and an average capitalized R&D cost of approximately $2-3.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -645M | -645M | -464M | -328M | -239M | -186M |
| EPS | $-1.44 | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 |
| Free Cash Flow | -378M | -378M | -373M | -300M | -121M | -198M |
| ROIC | -107.9% | -58.8% | -44.0% | -70.6% | -49.2% | -34.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.08 | 0.08 | 0.11 | 0.11 | 0.11 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -648M | -648M | -479M | -350M | -246M | -183M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -57.0% | -59.5% | -44.8% | -70.8% | -49.3% | -34.3% |
| Shares Outstanding | 448M | 448M | 274M | 208M | 176M | 125M |
| Metric | 2020 | 2021 | 2022 | 2023 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 63M | 135M | 156M | 241M | 314M | 475M | 475M |
| SG&A | 25M | 58M | 82M | 111M | 178M | 177M | 177M |
| EBIT | -85M | -183M | -246M | -350M | -479M | -648M | -648M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -87M | -186M | -239M | -328M | -464M | -645M | -645M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 9.8M | 9.8M |
| Returns on Capital | |||||||
| ROIC | -28.3% | -34.3% | -49.2% | -70.6% | -44.0% | -58.8% | -107.9% |
| ROE | N/A | -34.3% | -49.3% | -70.8% | -44.8% | -59.5% | -57.0% |
| ROA | -29.1% | -30.6% | -34.1% | -50.2% | -32.0% | -44.1% | -43.7% |
| Cash Flow | |||||||
| Op. Cash Flow | -45M | -159M | -84M | -288M | -359M | -372M | -372M |
| Free Cash Flow | -51M | -198M | -121M | -300M | -373M | -378M | -378M |
| Owner Earnings | -54M | -182M | -123M | -366M | -477M | -567M | -567M |
| CapEx | 5.8M | 40M | 37M | 12M | 14M | 6.5M | 6.5M |
| Maint. CapEx | 3.9M | 8.4M | 12M | 24M | 36M | 84M | 84M |
| Growth CapEx | 1.9M | 31M | 25M | 0 | 0 | 0 | 0 |
| D&A | 3.9M | 8.4M | 12M | 24M | 36M | 84M | 84M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 4.3M | 15M | 28M | 54M | 82M | 111M | 111M |
| Debt Repayment | 77K | 13M | 90K | 766K | 4.4M | 8.4M | 8.4M |
| Balance Sheet | |||||||
| Net Debt | -249M | -516M | -1.0B | -732M | -1.1B | -1.4B | -656M |
| Cash & Equiv. | 262M | 285M | 550M | 392M | 594M | 743M | 743M |
| Long-Term Debt | 11M | 633K | 536K | 1.1M | 19M | 9.6M | 9.6M |
| Debt/Equity | -0.07 | 0.00 | 0.11 | 0.11 | 0.11 | 0.08 | 0.08 |
| Interest Coverage | -85.6 | -61.9 | -4467.8 | -3608.9 | -304.7 | -358.1 | -358.1 |
| Equity | -206M | 543M | 486M | 463M | 1.0B | 1.1B | 1.1B |
| Total Assets | 299M | 610M | 701M | 654M | 1.4B | 1.5B | 1.5B |
| Total Liabilities | 57M | 67M | 215M | 190M | 414M | 343M | 343M |
| Intangibles | 1.7M | 1.4M | 1.3M | 36M | 336M | 310M | 310M |
| Retained Earnings | -214M | -400M | -640M | -968M | -1.4B | -2.1B | -2.1B |
| Working Capital | 243M | 488M | 470M | 345M | 527M | 665M | 665M |
| Current Assets | 266M | 535M | 570M | 438M | 714M | 813M | 813M |
| Current Liabilities | 23M | 47M | 100M | 93M | 187M | 148M | 148M |
| Per Share Data | |||||||
| EPS | -3.99 | -1.49 | -1.36 | -1.58 | -1.69 | -1.44 | -1.44 |
| Owner EPS | -0.31 | -1.45 | -0.70 | -1.76 | -1.74 | -1.27 | -1.27 |
| Book Value | -1.21 | 4.34 | 2.76 | 2.23 | 3.77 | 2.53 | 2.53 |
| Cash Flow/Share | -0.27 | -1.27 | -0.47 | -1.39 | -1.31 | -0.83 | -1.25 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 170.8M | 125.2M | 176.1M | 207.6M | 274.4M | 447.7M | 447.7M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -2.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 3.9 | 2.6 | 4.8 | 2.0 | 1.7 | 1.4 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -9.4% | -9.5% | -13.6% | -18.4% | -19.9% | -23.9% |
| Market Cap | N/A | 2.1B | 1.3B | 2.2B | 2.0B | 1.9B | 1.6B |
| Avg. Price | N/A | 25.48 | 9.46 | 8.00 | 8.42 | 5.61 | 3.54 |
| Year-End Price | N/A | 16.89 | 7.20 | 10.61 | 7.39 | 4.25 | 3.54 |
RECURSION PHARMACEUTICALS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
RECURSION PHARMACEUTICALS, INC. (RXRX) has a 5-year average return on invested capital (ROIC) of -51.4%. This is below average and may indicate limited pricing power.
RECURSION PHARMACEUTICALS, INC. (RXRX) has a market capitalization of $1.6B. It is classified as a small-cap stock.
RECURSION PHARMACEUTICALS, INC. (RXRX) does not currently pay a regular dividend.
RECURSION PHARMACEUTICALS, INC. (RXRX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
RECURSION PHARMACEUTICALS, INC. (RXRX) generated $-378 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
RECURSION PHARMACEUTICALS, INC. (RXRX) has a debt-to-equity ratio of 0.08. This indicates a conservatively financed balance sheet.
RECURSION PHARMACEUTICALS, INC. (RXRX) reported earnings per share (EPS) of $-1.44 in its most recent fiscal year.
RECURSION PHARMACEUTICALS, INC. (RXRX) has a return on equity (ROE) of -59.5%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for RECURSION PHARMACEUTICALS, INC. (RXRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
RECURSION PHARMACEUTICALS, INC. (RXRX) has a book value per share of $2.53, based on its most recent annual SEC filing.